Professional Documents
Culture Documents
Patient Monitoring Devices Global Market - Forecast To 2027
Patient Monitoring Devices Global Market - Forecast To 2027
–Forecast to 2027
IQ4I Research & Consultancy published a new report on “Patient Monitoring Devices
Global Market – Forecast To 2027” This report analyzes and studies the overall market,
major Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific
and Rest of the World.
IQ4I’s Report Contains 229 market data tables and 260 figures spread through 773
pages and an exhaustive TOC on “PATIENT MONITORING DEVICES GLOBAL MARKET”,
[DEVICE TYPE (Neuro {EEG, Cerebral oximeter, ICP, MEG, Electromyograph},
Hemodynamic {BP, Cardiac Output}, Blood Glucose {CGM, SBGM}, Cardiac {Event,
12-Lead ECG, Holter}, Fetal & Neonatal {Fetal Monitor, Doppler, Infant Incubator,
Neonatal Monitors}, Respiratory {Capnography, Anesthesia, Polysomnography, Pulse
oximeter (Fingertip, Handheld, Tabletop, Other Oximeters), Other respiratory devices},
Multi-parameter {High, Mid and Low acuity}, Temperature {Digital, Infrared, Others}
and Remote patient monitoring {Hemodynamic, Neuro, Cardiac, Multi-parameter}),
PORTABILITY (Stationary, Portable, wearable, Implantable), END-USER (Hospitals,
Ambulatory, Homecare, Others) GEOGRAPHY (North America, Europe, APAC and
RoW)].
Patient monitoring devices are the systems used for monitoring physiological signals
including blood pressure, oxygen saturation, body temperature, heart rate, blood glucose
level, brain activity and other parameters to understand the health status of the patient
during surgery, post-surgery care and treatment at a healthcare facility or home. According
to the American Hospital Association, in 2018, there were about 36.3 million hospital
admissions in U.S., similarly, in the U.K., there were 17.1 million admissions for treatment of
various health conditions. During these admissions, patient monitoring equipment plays an
important role in assessing vital health information which makes the difference between life
and death.
According to IQ4I analysis, the patient monitoring devices global market is expected to grow
at a mid-single-digit CAGR from 2020 to 2027 to reach $42,974.9 million by 2027. The
factors such as, increase in the rate of surgeries and diseased population requiring
continuous monitoring, increasing demand for portable and remote patient monitoring,
increasing funding and investment in patient monitoring are driving the market growth,
favorable reimbursement policies, technological advancements such as wireless technology,
biosticker, use of artificial intelligence and IOT are providing opportunities for the growth.
Whereas, the high cost of patient monitoring devices and patient safety and inaccuracy
concerns, increased product recalls are restraining the market growth. The threat includes
lack of cybersecurity in wireless patient monitoring devices and stringent regulatory
requirements for new product approvals.
–Forecast to 2027
The patient monitoring devices global market is segmented based on device, portability,
end-users and geography. Among devices, the blood glucose monitoring segment
commanded the largest revenue in 2020 and is expected to grow at a low single-digit CAGR
from 2020 to 2027. Remote patient monitoring segment is expected to grow at a high single-
digit CAGR of from 2020 to 2027 as remote patient monitoring (RPM) allows healthcare
providers to monitors patients outside of the clinical setting, help in the management of
chronic diseases, improves patient outcome and reduce healthcare delivery costs.
The market based on the portability is segmented into stationary, portable, wearable and
implantable devices. Among these, the portable devices segment commanded the largest
revenue in 2020 and is expected to grow at a mid-single-digit CAGR from 2020 to 2027.
Increasing applications such as cardiac, respiratory, cancer and advantages of the portable
devices such as ease to use, low-cost sensor technologies, low power consumption,
miniaturized devices and reliability are advantages of portable medical devices that patients
can use in the comfort of their homes are some of the factors driving the market.
The market based on end-user is segmented into hospital, ambulatory, homecare and
others. Among these, the hospital segment commanded the largest revenue in 2020 and is
expected to grow at a low single-digit CAGR from 2020 to 2027. The home healthcare
market is expected to be the fastest-growing segment with a mid-single-digit CAGR from
2020 to 2027. An increase in the elderly population, need for individual attention, patient
comfort, reduced complications and better patient outcomes are the factors driving the home
healthcare market.
The market based on geographies is segmented into North America, Europe, Asia Pacific
and the Rest of the world regions. Among these, North America commanded the largest
share in 2020 and the market is expected to grow at a low single-digit CAGR from 2020 to
2027. An increase in patient population and an increase in funding on developing sleep
apnea diagnostic and therapeutic devices are the factors driving the market. Asia Pacific is
expected to grow at a strong mid-single-digit CAGR from 2020 to 2027.
Market developments like approvals, agreements and acquisitions are driving the patient
monitoring devices global market growth. For example, In June 2020, Dexcom received CE
Mark approval for its G6 continuous glucose monitoring systems. The Dexcom G6 is
available for patients in Europe over the age of two and can be worn on the abdomen, as
well as on the back of the upper arm. Similarly, in December 2019, Masimo and Drager
–Forecast to 2027
expanded their agreement, whereby Drager will integrate additional Masimo measurement
technologies into Drager family of multi-parameter patient monitors, to help clinicians assess
brain function, oxygenation, and ventilation status.
Considering the attractiveness of the patient monitoring market, several venture capitalists
are investing in nurturing new technologies or increasing market access for advanced
technologies. According to IQ4I analysis, the reported funding received by companies during
the period 2018-2020 was worth ~$XX million. For instance, In May 2020, the company
Siren received $XX million from Anthem ventures to help commercial expansion, the
company’s portfolio includes a temperature-monitoring sock capable of connecting wirelessly
to a software application, allowing podiatrists to detect early signs of inflammation in people
who are at risk of developing diabetic foot ulcers. Similarly, in February 2020, CloudCath
received $XX million from Capital Integral for developing a real-time system for monitoring
patients undergoing dialysis at home. Patient monitoring devices clinical trials data indicate
that 42.9% clinical trials are in phase 3 stage, XX% clinical trials are in phase-2 and XX%
clinical trials are in phase-1 for developing continuous non-invasive blood pressure
monitoring, Insertable cardiac monitor and CGM devices.
According to IQ4I analysis, the patient monitoring market is fragmented and the major
players such as Abbott Laboratories, Medtronic, PLC, Dexcom, Inc., Koninklijke Philips N.V.,
Masimo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Nihon Kohden,
DragerWerk A.G., Omron., GE Healthcare, Hill-Rom Holdings, Inc. (Welch Allyn) and
–Forecast to 2027
Edwards Lifesciences Corporation, occupying the share of XX% of the market, among these,
Abbot Laboratories is recognized as the global leader with the largest share of XX% of the
overall market in 2020.
Device cost plays a crucial role in the adoption of patient monitoring devices, according to
IQ4I analysis, the average selling price (ASP) of the EEG is considered to be $XX in North
America whereas the same in APAC region is $XX, this high cost is inhibiting the adoption
and only XX in N.A. and XX in APAC were estimated to have been sold respectively.
Similarly, the ASP of ICP is considered to be $XX in Europe and $XX in RoW, the
expensiveness of the advanced device is inhibiting its penetration resulting in the sale of an
estimated-only XX units in RoW. The average life span of patient monitoring devices is 2 to 5
years, for example, ICP 5 years, whereas that of EEG 2 years respectively. Similarly, all
patient monitoring devices units sold and installed base have been calculated.
Major players in patient monitoring devices global market are Medtronic, PLC (Ireland),
Dexcom, Inc. (U.S.), Masimo Corporation (Switzerland), Abbott Laboratories (U.S.),
BioTelemetry, Inc. (U.S.), Edwards Lifesciences Corporation (U.S.), GE Healthcare (U.S.),
Koninklijke Philips N.V. (Netherlands), Hill-Rom Holdings, Inc. (U.S.), Natus Medical, Inc.
(U.S.), Dragerwerk AG & Co. KGaA (Germany), Shenzhen Mindray Bio-Medical Electronics
Co., Ltd. (China), Nihon Kohden Corporation (Japan), OSI Systems (Spacelabs Healthcare)
(U.S.), ICU Medical (U.S.), Baxter International (U.S.), Honeywell Life sciences (U.S.),
Smiths Medical (U.S.), Lidco Group (U.K.), and other companies
–Forecast to 2027
–Forecast to 2027
FIGURE 1
Respiratory
Monitoring
Multi-Parameter
Temperature
Monitoring
Remote Patient
Monitoring